TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a first-person report published by Being Patient on Oct. 6, 2026, patient advocate Ron Carr recounts three health notifications that changed how he viewed Alzheimer’s risk and prevention. The available source details his APOE4 genetic result and a coronary calcium scan showing coronary plaque; the third notification is not included in the supplied excerpt.
Patient advocate Ron Carr described how an APOE4 genetic test result and a coronary artery calcium scan changed his view of Alzheimer’s risk and heart health in a first-person report published by Being Patient on Oct. 6, 2026. The supplied excerpt begins a story about three health notifications but details only the first two, so the third notification and the full account’s conclusion cannot be confirmed from the available material.
Carr wrote that he learned two years before publication that he carries two copies of APOE4, a genetic variant associated with increased risk of late-onset Alzheimer’s disease, though some genes may protect against APOE4-related risk. He described feeling alarmed and becoming preoccupied with ordinary lapses, while emphasizing in retrospect that APOE4 is a risk factor, not a diagnosis. His account is a personal experience, not evidence that genetic testing predicts an individual’s outcome.
Carr said he responded by extensively researching Alzheimer’s, changing his diet and exercise routines, taking supplements, and using prescription sleeping pills that left him groggy and irritable. Over time, he wrote, learning more helped him feel less helpless and focus on health risks he believed he could influence. The account does not establish that any particular diet, supplement or routine prevents Alzheimer’s.
The second notification came after a clinician at the USC Center for Personalized Brain Health discussed APOE4’s role in lipid transport and Carr underwent a coronary calcium scan. He said the scan showed significant calcified plaque, concentrated largely in his left anterior descending artery. Carr wrote that he was then diagnosed, at age 65, with atherosclerotic cardiovascular disease and that his clinician lowered his LDL cholesterol and ApoB targets. He reported that follow-up testing showed no structural heart damage; the excerpt does not provide scan measurements or clinical records.
How Genetic Risk Led to a Heart Scan
Carr’s account illustrates how a genetic result can prompt broader conversations about health, while also showing that risk information and a clinical diagnosis are different. His APOE4 result did not mean he had Alzheimer’s disease. The subsequent heart scan, as he described it, identified coronary plaque and led to changes in his cardiovascular care.
The distinction matters to readers considering genetic tests or preventive screening: a risk marker may inform a discussion with a clinician, but it does not determine a person’s future. Carr’s experience also underscores that findings and treatment decisions depend on an individual’s medical history and clinical assessment. The source is a patient narrative, not a study establishing that APOE4 testing should routinely lead to coronary imaging.
genetic testing kits for Alzheimer's risk
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From APOE4 Result to Coronary Imaging
Carr is identified by Being Patient as a retired local government executive and patient advocate focused on Alzheimer’s prevention, genetic testing and cardiovascular health. He said his father had a heart attack at 65, a family experience that informed his own attention to heart health. Carr wrote that he had been a distance runner, adopted a heart-conscious diet and eventually accepted statin therapy, with cholesterol levels his physician considered acceptable before the scan.
In discussing dementia risk, Carr cited the Lancet Commission estimate that up to 45% of dementia cases may be attributable to potentially modifiable risk factors. That figure is an estimate about population-level risk factors; it does not mean an individual can prevent dementia or reduce personal risk by a fixed amount. The supplied account does not provide the commission report’s methods or discuss how the estimate applies to Carr.
“APOE4 is not a diagnosis. It is a risk factor.”
— Ron Carr, writing in Being Patient
As an affiliate, we earn on qualifying purchases.
The Third Notification Is Missing
The supplied source material ends during Carr’s account of his heart scan and the conversations he began having with people close to him. It does not identify the third health notification, describe any related test or result, or give the full account’s ending. Those details cannot be responsibly inferred from the headline.
The excerpt also does not give Carr’s APOE4 test provider, the coronary scan’s numerical score, the exact medication changes, or the dates and measurements from follow-up testing. His reported experiences and treatment are not independently verified in the material provided, and the account does not establish a general medical recommendation.
As an affiliate, we earn on qualifying purchases.
Full Account Needed for the Final Alert
The next step for readers seeking the complete three-part story is to consult the full Being Patient report, which may contain the omitted notification and Carr’s subsequent reflections. Until that material is available, the confirmed scope of this report should remain limited to the APOE4 result and coronary calcium scan described in the excerpt.
Readers weighing genetic testing, cardiovascular imaging or changes to medication should discuss their circumstances with a qualified health professional. Carr’s account describes his own decisions and clinician’s advice; it does not establish what screening or treatment is appropriate for others.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are the two health notifications described in the available excerpt?
Carr describes learning he carries two copies of APOE4, then receiving a coronary calcium scan that he said showed significant calcified plaque. The excerpt does not identify the third notification.
Does carrying APOE4 mean someone has Alzheimer’s disease?
No. Carr describes APOE4 as a risk factor, not a diagnosis. The account does not say that he was diagnosed with Alzheimer’s disease.
What did Carr say his heart scan found?
He reported significant calcified plaque in his coronary arteries, most of it concentrated in the left anterior descending artery. The supplied excerpt gives no numerical scan score.
What is not known from the supplied report excerpt?
The excerpt does not reveal the third notification, the story’s ending, scan measurements or detailed treatment records. It also does not establish that Carr’s experience applies to other people.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
